Physician profile
Ramon Ramirez
NPI 1760008304
$5,599.20
in general payments reported to CMS, 2019-2025
25 companies · $3,804 in 2025
The $3,804 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,795 · 2025: $3,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,524 · Education: $74.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,524.34 |
| Education | $74.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,629.27 | 2024-2025 | Fasenra, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $678.36 | 2024-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Genzyme Corporation | $505.64 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $415.10 | 2024-2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $321.75 | 2024-2025 | Ofev, Jascayd |
| Takeda Pharmaceuticals U.S.A., INC. | $311.16 | 2024-2025 | Glassia, Hyqvia |
| Mallinckrodt Hospital Products INC. | $239.49 | 2024-2025 | Acthar |
| United Therapeutics Corporation | $222.38 | 2024-2025 | Tyvaso, Tyvaso |
| Pulmonx Corporation | $193.66 | 2024-2025 | Zephyr Endobronchial Valve, Chartis Catheter, Zephyr Delivery Catheter |
| Viatris Specialty LLC | $171.45 | 2025 | Yupelri |
| Amgen INC. | $130.03 | 2024-2025 | Tezspire |
| Electromed, INC. | $120.94 | 2025 | Smartvest |
| Mylan Specialty L.P. | $114.08 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $93.77 | 2024-2025 | Zerbaxa, Dificid |
| Insmed, INC. | $89.18 | 2025 | Arikayce |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $76.79 | 2025 | Ohtuvayre |
| Sanofi-Aventis U.S. LLC | $57.48 | 2025 | |
| Abbvie INC. | $38.82 | 2025 | |
| Optinose US, INC. | $37.71 | 2024-2025 | |
| Ani Pharmaceuticals, INC. | $34.57 | 2025 | Purified Cortrophin Gel |
| Harmony Biosciences LLC | $28.55 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $26.40 | 2025 | Opsynvi, Uptravi |
| Philips North America LLC | $24.87 | 2024 | (Ak6) Vest Therapy |
| Novo Nordisk INC | $22.75 | 2024 | Wegovy |
| Breas Medical, INC. | $15.00 | 2025 | Vivo 45 Ls |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramon Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.